Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804306 · ClinicalTrials.gov registry record
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 198
- Enrollment target
NCT04804306: Completed study, sponsored by Beckman Coulter.
NCT04804306 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 198 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04804306 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 198 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).
Primary Outcome
MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated
Interventions
- DEVICE Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2021-09-05 |
| Est. Completion | 2022-06-06 |
What the finished NCT04804306 record still lists
NCT04804306 is an observational study that tracks outcomes without assigning an intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW) is the first listed.
NCT04804306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04804306 about?
NCT04804306 is a clinical study titled "Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC". The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentatio...
What is the current status of trial NCT04804306?
This trial is currently completed. The enrollment target is 198 participants. The study started on 2021-09-05. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT04804306?
The interventions under investigation include: Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW) (DEVICE).
Who is sponsoring clinical trial NCT04804306?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI